{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:29:32Z","timestamp":1789010972173,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"s66","license":[{"start":{"date-parts":[[2005,6,6]],"date-time":"2005-06-06T00:00:00Z","timestamp":1118016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Utilising the Scotland and Newcastle Lymphoma Group population data for Hodgkin's disease (HD), collected over a 20\u2010year period, it is evident that 20% of patients are over the age of 60\u2003yr at diagnosis. Data from 674 patients are available. This group comprised 346 men and 328 women. Median follow\u2010up was 9.5\u2003yr. In total 361 patients had stage I\/II disease. In this cohort overall response and complete response (CR) rates were 88% and 79%, respectively, for treated patients. Overall 308 patients had stage III\/IV disease. Among treated patients in this cohort, overall and CR rates were 78% and 59%, respectively. Response data were missing for 26 patients with stage I\/II disease and 43 patients with stage III\/IV disease. The chlorambucil, vinblastine, procarbazine and prednisolone, mechlorethamine, vincristine, probarbazine and prednisolone and doxorubicin, bleomycin, vinblastine and decarbazine were the commonest chemotherapy regimens, in descending order of frequency, used to treat this cohort of patients. Outcome did not vary with these regimens. Thirty\u2010four other chemotherapy combinations were used, some curative others palliative. These data and all other published studies confirm the need for a prospective, age\u2010defined approach to HD in the elderly. Such an approach needs to be closely linked to issues of comorbidity, an assessment of frailness and the tailoring of specific protocols for the elderly to allow full dose delivery. The Study of Hodgkin Lymphoma In the Elderly\/Lymphoma Database programme has now been launched and attempts to address these issues (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.shieldstudy.co.uk\">http:\/\/www.shieldstudy.co.uk<\/jats:ext-link>).<\/jats:p>","DOI":"10.1111\/j.1600-0609.2005.00457.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T01:34:21Z","timestamp":1279416861000},"page":"63-67","source":"Crossref","is-referenced-by-count":24,"title":["An international approach to the treatment of Hodgkin's disease in the elderly: launch of the SHIELD study programme"],"prefix":"10.1111","volume":"75","author":[{"given":"Stephen J.","family":"Proctor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,6,6]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/13.S1.133"},{"key":"e_1_2_5_3_2","first-page":"889","article-title":"Effect of age on therapeutic response and survival in advanced Hodgkin's disease","volume":"66","author":"Peterson BA","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840301)53:5<1202::AID-CNCR2820530530>3.0.CO;2-L"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840515)53:10<2191::AID-CNCR2820531031>3.0.CO;2-0"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1989.tb00268.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050521"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<395::AID-CNCR24>3.0.CO;2-W"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1582"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00090-4"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh012"},{"key":"e_1_2_5_12_2","article-title":"Population projections by the government actuary","author":"Office of Population Censuses and Surveys","year":"1991","journal-title":"HMSO"},{"key":"e_1_2_5_13_2","unstructured":"General Register Office for Scotland. Scotland's Census 29 April 2001.http:\/\/www.scrol.gov.uk:2004."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.187"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211193272102"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03815.x"},{"key":"e_1_2_5_17_2","first-page":"1707","article-title":"Symposium sponsored by the American Cancer Society and the National Cancer Institute, Ann Arbor, Michegan","volume":"31","author":"Ann Arbor Staging System","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.1991.9.6.947","article-title":"The prognosis of Hodgkin's disease in older adults","volume":"9","author":"Guinee VF","year":"1991","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920815)70:4<830::AID-CNCR2820700418>3.0.CO;2-X"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418602321028283"},{"key":"e_1_2_5_21_2","first-page":"450","article-title":"Results of a low aggressivity chemotherapy regimen (CVP\/CEB) in elderly Hodgkin's disease patients","volume":"81","author":"Levis A","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_5_22_2","first-page":"729","article-title":"Efficacy of VBM regimen in the treatment of elderly patients with Hodgkin's disease","volume":"85","author":"Zinzani PL","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi023"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290033332"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.4.1087"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02897235"},{"key":"e_1_2_5_27_2","first-page":"340","article-title":"CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin's disease","volume":"75","author":"Brusamolino E","year":"1990","journal-title":"Haematologica."},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058874"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2005.00457.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2005.00457.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:24:17Z","timestamp":1695716657000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2005.00457.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,6]]},"references-count":27,"journal-issue":{"issue":"s66","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1600-0609.2005.00457.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00457.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,6]]}}}